GlassScriptPhysician profile
Michael F Foley
NPI 1235365784
$10,970.91
in general payments reported to CMS, 2019-2025
40 companies · $2,960 in 2025
The $2,960 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $533 · 2021: $1,435 · 2022: $1,228 · 2023: $1,738 · 2024: $2,620 · 2025: $2,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,269 · Education: $48.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,268.76 |
| Education | $48.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,562.13 | 2019-2025 | |
| Janssen Biotech, INC. | $984.83 | 2019-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $958.75 | 2019-2025 | |
| Genzyme Corporation | $908.35 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $882.28 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $748.85 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Madrigal Pharmaceuticals | $581.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $482.44 | 2021-2024 | Zeposia |
| Pfizer INC. | $477.89 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $269.45 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $252.64 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $247.39 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $222.47 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $219.00 | 2021-2024 | Dificid |
| Lilly USA, LLC | $143.14 | 2024-2025 | Omvoh |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Foley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.